Copies of extract of Audited Standalone Financial Results of the Company for the quarter and financial year ended March 31, 2026 as published in today''s newspaper, i.e., April 30, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Zenotech Laboratories reported Total Income of Rs 4,592.26 lakhs for FY26, up 3% from Rs 4,459.57 lakhs in FY25. However, the company posted a net loss of Rs 107.21 lakhs for the full year, a sharp decline from profit of Rs 561.29 lakhs in FY25. Q4 FY26 showed improvement with net profit of Rs 122.98 lakhs versus Q4 FY25 profit of Rs 192.56 lakhs. EPS for FY26 was negative at Rs -0.18 per share (face value Rs 10). The results were reviewed by the Audit Committee and approved by the Board on April 29, 2026, and published in newspapers on April 30, 2026 as per SEBI listing regulations.
The full-year loss is concerning for shareholders as the company swung from profitability to loss. However, Q4 profitability suggests some recovery. Investors should monitor whether the Q4 turnaround is sustainable or if the company faces continued headwinds.